BMO cuts Medpace stock price target on cancellation concerns

MEDP is starting to trade less like a clean compounder and more like a bookings-confidence story, which matters because CRO valuation compressions usually happen before the fundamentals visibly roll over. The market is discounting not just a softer 2026 path, but a higher probability that cancellations are leading gross wins by a couple of quarters; if that sequencing persists, 2027 EBITDA estimates are still too high and the multiple can de-rate another 2-3 turns without any near-term revenue miss.

The second-order effect is on capital allocation across outsourced clinical research: if a high-quality operator is being questioned on booking durability, smaller CROs and adjacent service providers with less visibility will likely be punished harder on any similar soft guidance. That creates a relative-value setup where the market may over-penalize peers with cleaner pipeline conversion or more diversified sponsor mix, while also making large-pharma internalization more attractive if CRO pricing power appears unstable.

The key catalyst window is the next 1-2 quarters, not the full-year 2026 guide. If cancellations normalize and gross bookings re-accelerate, the stock can quickly re-rate back toward the high-$400s because the current concern is credibility, not solvency; if not, downside likely comes from estimate cuts rather than multiple alone. The contrarian read is that the selloff in the broader healthcare/tools complex is reinforcing a mechanical de-risking trade, so MEDP may be getting sold with the group even though the real issue is narrower and should be judged on bookings conversion.

The note on INTC appears headline-only and should not be overread into this setup; the actionable signal here is the market’s willingness to pay up for earnings beats when guidance quality is questioned. That means the first positive bookings print could matter more than another EPS beat, because it would attack the core bear case directly.